Hereditary Cancer Panel denied as experimental or investigational by Blue Cross Blue Shield?
An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Blue Cross Blue Shield typically requires
Blue Cross Blue Shield's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Blue Cross Blue Shield angle on Hereditary Cancer Panel
## Why This Denial Happens
BCBS plans may deny multi-gene hereditary cancer panels as "experimental" or "investigational" by applying coverage-policy language that has not kept pace with the rapid adoption of panel testing in clinical practice. This denial is most common when the plan's medical policy was last updated before comprehensive panel testing became a guideline-supported standard of care, or when the specific panel ordered includes genes beyond a narrow list the plan has explicitly approved. It is one of the most frustrating denials because the technology is widely used in clinical practice and endorsed by major guideline organizations.
## Why This Is Appealable
The "experimental" label requires BCBS to show that the service lacks sufficient evidence of clinical effectiveness. Independent external reviewers — who are required to apply current, peer-reviewed evidence — routinely overturn these denials when the ordering clinician documents that the test is consistent with the applicable NCCN or equivalent guideline organization's recommendations for the patient's clinical presentation. The external review right under ACA §2719 is particularly powerful here because the reviewer is not bound by BCBS's internal policy language.
## Federal Appeal Framework
- Internal appeal: File within the deadline on your denial notice. BCBS must respond within the applicable timeframe (30 days for pre-service standard; 72 hours expedited).
- External review (ACA §2719): After final internal denial, request independent external review — generally within four months. The reviewer applies objective evidence standards, not BCBS's policy language.
- Expedited external review: Available when the patient's condition is urgent or when the standard timeline would seriously jeopardize health.
- ERISA §503: For self-funded plans, full-and-fair review is required; federal court available after exhaustion.
- State insurance commissioner: For fully-insured plans, file a complaint in parallel; many states require coverage of guideline-supported genetic testing.
## Documentation to Gather
1. Ordering clinician's letter citing the applicable guideline organization (e.g., NCCN) by name and stating that the patient meets the published criteria for testing — without quoting specific numbers, but referencing the guideline document by title and version. 2. Clinical and family history establishing the indication that triggered the guideline-based recommendation. 3. Published guideline reference — the guideline organization's publicly available document (not a quotation, but the document itself as an exhibit). 4. Literature or technology assessment from the ordering lab or a professional society supporting the clinical validity of the specific panel. 5. BCBS medical policy — obtain the current version and the version in effect on the date of service to identify whether the policy has been updated.
## Criteria-Mapping Structure
BCBS's experimental-coverage policy typically requires absence of sufficient clinical evidence. Build a two-column table with each element of that definition on the left, and on the right, cite the specific guideline document, professional society position, or clinical evidence the ordering clinician is relying on. Attach the guideline document as a labeled exhibit. The goal is to make the reviewer's job easy: every evidentiary basis for coverage is in front of them, organized to answer the policy's own criteria.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Blue Cross Blue Shield denied as experimental or investigational of 17ohp Compounded
- Blue Cross Blue Shield denied as experimental or investigational of AAT Augmentation
- Blue Cross Blue Shield denied as experimental or investigational of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied as experimental or investigational of Anti Cd 20 Ocrevus